Replimune Group, Inc. announced on January 8, 2025, that the first patients have been enrolled in clinical studies evaluating its product candidate, RP2, in two distinct settings. These include checkpoint-naive metastatic uveal melanoma and second-line recurrent or metastatic hepatocellular carcinoma (HCC).
RP2 is based on a proprietary strain of herpes simplex virus engineered to express a fusogenic protein (GALV-GP R-), GM-CSF, and an anti-CTLA-4 antibody-like molecule. This design aims to provide targeted delivery of immune-stimulating proteins to tumor sites and draining lymph nodes, potentially limiting off-target toxicity.
This pipeline advancement follows the recent Biologics License Application submission for RP1 and its Breakthrough Therapy designation. The initiation of these trials for RP2 demonstrates Replimune's continued commitment to expanding its oncolytic immunotherapy platform across a broader range of cancer indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.